ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sarepta Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on August 25, 2025 [1] Group 1: Class Action Details - Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Rosen Law Firm has been recognized for its performance in securities class action settlements, being ranked No. 1 in 2017 and consistently in the top 4 since 2013 [4] Group 3: Case Specifics - The lawsuit alleges that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [5] - Key issues raised include significant safety risks associated with ELEVIDYS, failure to detect severe side effects in trials, and the potential for regulatory scrutiny due to adverse events [5] - The lawsuit claims that these misrepresentations led to investor damages when the true information became public [5]